0001193125-20-320037.txt : 20210121 0001193125-20-320037.hdr.sgml : 20210121 20201217160028 ACCESSION NUMBER: 0001193125-20-320037 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 CORRESP 1 filename1.htm CORRESP

NEOLEUKIN THERAPEUTICS, INC.

360-1616 Eastlake Avenue East

Seattle, Washington 98102

December 17, 2020

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Attention:   

Margaret Schwartz

Office of Life Sciences

           Re:   

Neoleukin Therapeutics, Inc.

Registration Statement on Form S-3

Filed December 11, 2020

File No. 333-251294

Via EDGAR—Acceleration Request

Requested Date:            December 21, 2020

Requested Time:           4:00 p.m. Eastern Time

Ladies and Gentlemen:

Neoleukin Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

Sincerely,
NEOLEUKIN THERAPEUTICS, INC.
By:  

/s/ Robert Ho

  Robert Ho
  Chief Financial Officer

 

cc:   

Jonathan Drachman, Chief Executive Officer

Holly Vance, General Counsel

Neoleukin Therapeutics, Inc.

 

Robert Freedman, Esq.

Julia Forbess, Esq.

Fenwick & West LLP